Over the past 30 years, adolescents and young adults (AYA, 15–39 years of age) with cancer have shown significantly less improvement in survival than younger and older patients. Because evidence suggests this may be related to their low participation in cancer clinical trials, increasing accrual to these trials has become a priority for closing this “AYA gap.”

Authors: David R. Freyer and Nita L. Seibel

Read the article on the Springer Link website (subscription required)